v3.26.1
Segment Information - Schedule of Reportable Segments Reconcile of Segment Information (Details) - Operating Segments - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting Information [Line Items]    
Cost of drugs $ 2,672,793 $ 2,147,576
Cost of services 260,924 211,545
Other direct costs 197,782 180,639
Segment selling, general, and administrative expenses 279,456 205,840
Segment depreciation and amortization expense 32,282 34,277
Segment EBITDA 235,048 166,806
Products    
Segment Reporting Information [Line Items]    
Revenues 3,171,349 2,532,171
Services    
Segment Reporting Information [Line Items]    
Revenues 442,372 345,958
Pharmacy Solutions    
Segment Reporting Information [Line Items]    
Cost of drugs 2,672,793 2,147,576
Other direct costs 197,782 180,639
Segment selling, general, and administrative expenses 157,034 115,738
Segment depreciation and amortization expense 25,328 27,508
Segment EBITDA 169,068 115,726
Pharmacy Solutions | Products    
Segment Reporting Information [Line Items]    
Revenues 3,171,349 2,532,171
Provider Services    
Segment Reporting Information [Line Items]    
Cost of services 260,924 211,545
Segment selling, general, and administrative expenses 122,422 90,102
Segment depreciation and amortization expense 6,954 6,769
Segment EBITDA 65,980 51,080
Provider Services | Services    
Segment Reporting Information [Line Items]    
Revenues $ 442,372 $ 345,958